Stock Report

All about this stock under one free report Last Updated: 15-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Molecular Partners AG (MOLN) Key Ratios

Stock Card factsheet share-fund-plan-icon

$4.02

up-down-arrow $-0.16 (-3.83%)

As on 14-Sep-2026 16:00EDT

Market cap

info icon

$161 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2.2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -3.06 33.61 12.94 2.09 3.56
Net Profit -2.77 33.78 14.13 3.36 3.71
EPS 0.63 36.16 19.11 6.30 7.16
Book Value -- -- -48.40 -30.96 -12.92
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -983.42-645.75-----1,086.84
Net Margin info ----------
Return on equity info -39.88-22.06-82.60-55.55-33.98
Return on Capital info -38.97-21.24---54.07-33.34
Return on Assets info -34.84-17.15-51.56-47.31-30.29
Debt to Equity (x) info ----0.000.050.02

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
-54.07
-33.34
-29.51
66.71
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-82.60

Lower than Peers by 64.99

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
-82.60
-55.55
-33.98
-30.12
68.83
Peer Median
-17.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-51.56

Lower than Peers by 39.04

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
-51.56
-47.31
-30.29
-26.91
54.19
Peer Median
-12.52
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
-1,086.84
-880.01
61.52
Peer Median
-57.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
-1,087.38
-880.70
62.17
Peer Median
-62.35
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
-1.00
-0.29
-0.96
19.32
Peer Median
22.88
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

12.94

Lower than Peers by 1.26

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
12.94
-14.10
12.79
-153.11
284.44
Peer Median
14.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

14.13

Higher than Peers by 2.95

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
14.13
-14.08
12.81
-152.59
284.77
Peer Median
11.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

19.11

Lower than Peers by 9.84

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
19.11
-0.04
0.16
-1.58
2.21
Peer Median
28.94
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-47.27

Lower than Peers by 49.04

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
-47.27
--
--
--
--
Peer Median
1.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
0.05
0.02
0.02
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.02

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
0.02
0.02
0.01
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

7.27

Higher than Peers by 2.64

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
7.27
8.79
14.31
13.35
14.77
Peer Median
4.64
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

7.27

Higher than Peers by 2.67

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
7.27
--
--
--
--
Peer Median
4.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-1,406.09

Lower than Peers by 1,406.95

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
-1,406.09
-3,423.94
-2,160.64
-1,263.98
179.92
Peer Median
0.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
5.75
43.82
0.90
Peer Median
25.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
0.03
0.03
0.87
Peer Median
0.25
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
123.83
124.09
26.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
--
--
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
144.06
4.19
5.37
21.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Molecular Partners AG (MOLN)
--
--
--
--
5.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...